ASCO: Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approval

Pfizer and Astellas’ Xtandi is gunning for a new indication in prostate cancer, and they argue today's new data—showing the med cut the risk of death by a third—complement the evidence they’ve already generated.